Sucralfate: Effect as Mucosal Protection
Sucralfate (brand name Sulcrate and generics) is a basic aluminum salt of sulfated sucrose. It does not act systemically, but locally on damaged gastric and intestinal mucosa by forming a protective film over eroded or ulcerated areas. In Germany, sucralfate is an established second-line therapy for peptic ulcers, stress ulcer prophylaxis in intensive care medicine, and in specialized indications such as radiation-induced mucositis. Despite the dominant position of proton pump inhibitors, sucralfate has a firm place, especially in patients with comorbidities or drug interactions that limit other acid suppressants.
Compared to classic acid suppressants, sucralfate follows a different approach. It does not reduce stomach acid, but protects the mucosa mechanically and chemically. This preserves the stomach's natural acid function and microbiome to a large extent. This property is of interest in intensive care for stress ulcer prophylaxis because studies suggest a lower effect on the frequency of nosocomial pneumonia compared to PPI, although the data are not uniform.
Mechanism of Action
Sucralfate works through several local mechanisms. In the acidic environment of the stomach, the salt dissociates and forms a viscous, sticky mass that selectively binds to positively charged proteins in damaged mucosal tissue (for example, albumin and fibrinogen in the ulcer base). This creates a protective layer that shields the ulcer for 6 to 8 hours from further attacks by stomach acid, pepsin, and bile acids.
Additionally, sucralfate stimulates the production of protective factors such as prostaglandin E2 in the mucosa, promotes mucus and bicarbonate production, and supports mucosal blood flow. These cytoprotective effects complement the mechanical protection and accelerate ulcer healing. In radiation-induced or chemotherapy-induced mucositis, sucralfate works similarly by covering the mucosa and relieving pain.
Sucralfate is practically not absorbed systemically. A small amount of aluminum can accumulate with reduced kidney function, which is why caution is warranted in this situation. In the gastrointestinal tract, sucralfate acts locally and is excreted in the stool after its effect.
Indications
- Acute peptic ulcers in the stomach or duodenum, alone or in combination with acid suppressants
- Recurrence prophylaxis after ulcer healing, especially in patients without Helicobacter pylori infection or with ongoing NSAID therapy
- Reflux esophagitis as second-line therapy
- Stress ulcer prophylaxis in the intensive care unit in at-risk patients
- Chronic gastritis with mucosal damage, individual indication
- Radiation or chemotherapy-induced mucositis in specialized oncology settings
- Esophageal variceal bleeding as an adjuvant in specific situations
Sucralfate is not first-line therapy for acute upper gastrointestinal bleeding because endoscopic therapy and PPI are the focus here. In Helicobacter pylori eradication, antibiotics and PPI are used; sucralfate does not have a standard role there.
Dosage and Administration
Acute ulcer therapy: 1 g four times daily or 2 g twice daily. Treatment duration 4 to 8 weeks, depending on indication and endoscopic progression.
Recurrence prophylaxis: 1 g twice daily or 2 g once daily, individually.
Stress ulcer prophylaxis: 1 g four times daily, intravenous not available, administration via nasogastric tube possible.
Mucositis (off label): 1 to 2 g as a suspension multiple times daily after meals, briefly rinse in mouth or swallow.
Administration: on an empty stomach, at least one hour before a meal or two hours after. Take with plenty of water. Tablets can be dissolved in water, which facilitates use via nasogastric tubes.
Renal insufficiency: with eGFR below 30 ml per minute, caution due to minor aluminum absorption. With chronic use in this situation, consider regular aluminum levels, especially in dialysis patients.
Hepatic insufficiency: generally no dose adjustment required.
Side Effects
Common: Constipation, nausea, dry mouth, abdominal pain, belching, mild dizziness.
Occasional: Diarrhea, rash, pruritus, allergic reactions, feeling of dry mouth.
Rare, but relevant: Bezoar formation in the stomach with risk of mechanical problems, especially in gastric motility disorders or in infants. Hyperaluminemia and aluminum accumulation in chronic renal insufficiency, with potential bone and brain toxicity.
Hypophosphatemia: Sucralfate binds phosphate in the intestine, which can lead to reduced phosphate levels with prolonged therapy. With chronic use, monitoring of phosphate levels is worthwhile.
Topical application: With oral use as mucosal protection, no systemic side effects are expected, occasionally taste changes.
Drug Interactions
- Tetracyclines and fluoroquinolones (Doxycycline, Ciprofloxacin, Levofloxacin): significant reduction in absorption due to binding, maintain a minimum interval of two hours.
- Levothyroxine, Phenytoin, Digoxin, Warfarin, Theophylline: Reduced absorption possible, time interval advisable.
- H2 blockers and proton pump inhibitors: Combination possible, however, excessive acid suppression reduces the effect of sucralfate because acid activation is impaired. Maintain at least 30 minutes interval.
- Fat-soluble vitamins: With prolonged therapy, vitamins A, D, E, K may be reduced in absorption, individual observation.
- Antacids: Effect of sucralfate reduced at too high pH values, therefore staggered administration.
- Bile acid binders: Drug interactions possible, maintain minimum interval.
Special Information
Pregnancy: Due to low systemic absorption, sucralfate is considered well tolerated in pregnancy and can be used with clear indication. Breastfeeding: Transfer into breast milk is clinically not relevant, breastfeeding during therapy is unproblematic.
Children: Established in pediatrics, dosage adapted by weight. In infants, caution due to risk of bezoar formation.
Elderly patients: Caution with renal insufficiency due to aluminum accumulation.
Before starting therapy: Endoscopy for diagnosis, determine Helicobacter pylori status (breath test, antigen or endoscopy), review concomitant medication, especially with antibiotics and thyroid hormones, because sucralfate impairs their absorption.
Lifestyle with ulcer: Avoid nicotine, reduce alcohol and heavily spiced foods, regular meals, adequate sleep, NSAIDs with stomach protection or better avoidance. If NSAID needed long-term, consider PPI for protection.
When to see a doctor: With hematemesis, tarry stools, dizziness, weakness, persistent pain or fever, seek medical attention immediately. These symptoms may indicate bleeding.
Driving ability: Generally not restricted.
You might also be interested in
- Famotidine, H2 blocker for reflux and ulcer therapy
- Esomeprazole, Proton pump inhibitor as first-line therapy
- Cimetidine, older H2 blocker
- Dexketoprofen, NSAID with note on stomach protection
- Povidone, another excipient in mucosal applications
Frequently Asked Questions
Does sucralfate work differently than a proton pump inhibitor?
Yes. Proton pump inhibitors reduce stomach acid, sucralfate protects the mucosa mechanically and chemically. Both approaches promote ulcer healing, often PPIs are more effective and simpler to take. Sucralfate is a useful alternative for patients with comorbidities or indications such as stress ulcer prophylaxis.
Why must sucralfate be taken on an empty stomach?
An acidic stomach environment activates the salt and enables the formation of the protective layer. With a full meal, activation is reduced and binding to ulcers is weaker. Taking at least one hour before or two hours after meals ensures optimal effectiveness.
Can I combine sucralfate with other medications?
Yes, but with a time interval, because sucralfate reduces the absorption of many active substances. Maintain at least two hours interval from antibiotics, thyroid hormones, phenytoin, digoxin, warfarin, and antacids. A list of all medications should be discussed with your doctor or pharmacist.
Is sucralfate safe in pregnancy?
Due to very low systemic absorption, sucralfate is considered well tolerated in pregnancy. With clear indication such as reflux with mucosal lesions or ulcer, it can be used. Medical consultation is worthwhile because of individual factors.
Sources
- Gelbe Liste, Sucralfate Active Ingredient Profile
- BfArM, Federal Institute for Drugs and Medical Devices
- AWMF, Guidelines on Peptic Ulcers and Reflux
- German Society of Gastroenterology
Legal Notes and Disclaimer
The information provided on this page is for general information purposes only and does not constitute medical advice, diagnosis, or treatment recommendation. It does not replace the advice of a licensed physician or pharmacist. For acute or severe gastrointestinal complaints, medical evaluation is necessary. All information is based on expert information and recognized scientific sources published at the time of creation; the current expert information of the manufacturer is always authoritative. Sanoliste assumes no liability for completeness, currency, or accuracy of the information presented. In case of a medical emergency, call the emergency number 112.